

### AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 24, table 3 and ending at page 24 with the following replacement paragraph:

**Table 3: Examples of Additional PEDF Peptides**

<u>SEQ ID NO:</u>	<u>Sequence <sup>a</sup></u>	<u>Purpose</u>
<u>7</u>	VEEDP	TGA fragment
<u>8</u>	TGALV(QQQ)DPF	Varieties of mutated TGA
<u>9</u>	TGALVEEEDPFFKVPVNK	Extended TGA
<u>10</u>	EEEDPFFKVPVNK	TGA/34-mer fragment
<u>11</u>	TGASSEEDP	Improved solubility of TGA
<u>12</u>	PVNKLAAAVSNFGYDLYRVRSSMSP	hA fragment of the 34-mer
<u>13</u>	PVNKLAAAVSNFGYNLYRVRSSMSP	Mutated hA
<u>14</u>	KVPVNK	hA fragment
<u>15</u>	SNFGYD	hA fragment
<u>16</u>	YRVRSSMSP	hA fragment
<u>17</u>	DERTES	ERT-L fragment
<u>18</u>	HRALYYD	ERT-L fragment
<u>19</u>	YYDLIS	ERT-L vs. ERT-S
<u>20</u>	ERTESIIHRALYYNLIS	ERT-L vs. ERT-S
<u>21</u>	ERTESSHRALYYDSSS	Improved solubility of ERT-L
<u>22</u>	ERTESIIHRALYYDLISSPDIHGTYKELLD	hC-loop-hD
	TGA ± 34-mer ± ERT-L	Synergistic effects of active peptide mixtures
<u>23</u>	DERTESIIHRALYYDNNKVPVNKLAAAVSNFG	Permutation/ligation of hC and hA
<u>24</u>	TQVEHR	Gettins et al. (1996)

<sup>a</sup> All peptides will have acetyl groups on their amino terminus and amide groups on their carboxy terminus.

Application No. 10/529,500  
Amendment dated October 20, 2005  
Second Preliminary Amendment

Docket No.: 27611/39620A

**AMENDMENTS TO THE SEQUENCE LISTING**

Please insert the attached Sequence Listing (pages 1-8) into the above-referenced application.